Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 5/20 | 0.70 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.56 |
| ▸ | MASP2 | O00187 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170768 | 0.79 | ADORA1 (0.61) | NUDT1PSMB8MEN1ALDH1A1KMT2A | |
| SCHEMBL66295 | 0.79 | PSMB8 (0.59) | NUDT1PSMB8ALDH1A1ADORA1ADORA3 | |
| SCHEMBL3287778 | 0.79 | MEN1 (0.58) | NUDT1MASP2MEN1ALDH1A1KMT2A | |
| SCHEMBL30291834 | 0.79 | MEN1 (0.58) | NUDT1MASP2MEN1ALDH1A1KMT2A | |
| SCHEMBL14222708 | 0.76 | NUDT1 (0.51) | NUDT1MASP2MEN1ALDH1A1KMT2A | |
| SCHEMBL979914 | 0.76 | NUDT1 (0.51) | NUDT1MASP2MEN1ALDH1A1KMT2A | |
| SCHEMBL17276083 | 0.76 | NUDT1 (0.51) | NUDT1MASP2MEN1ALDH1A1KMT2A | |
| SCHEMBL727228 | 0.76 | MGAM (0.53) | NUDT1MASP2MEN1ALDH1A1KMT2A | |
| SCHEMBL11739880 | 0.76 | PSMB8 (0.56) | NUDT1PSMB8ALDH1A1ADORA1ADORA3 | |
| SCHEMBL17276019 | 0.76 | NUDT1 (0.51) | NUDT1MASP2MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771372-B2 | Compounds useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2017-09-26 | — | — | US | disclosed |
| US-20170204098-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2017-07-20 | — | — | US | disclosed |
| CN-106414448-A | Novel compounds useful as s100-inhibitors | 活跃生物技术有限公司 | 2017-02-15 | — | — | CN | disclosed |
| EP-2991990-B1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2017-02-01 | — | — | EP | disclosed |
| EP-2991990-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | Active Biotech AB (SE) | 2016-03-09 | — | — | EP | disclosed |
| WO-2015177367-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2015-11-26 | — | — | WO | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20030100592-A1 | Compounds and methods for use thereof in the treatment of viral infections | UNIVERSITY OF ARIZONA FOUNDATION (US) | 2003-05-29 | — | — | US | disclosed |
| US-20020193609-A1 | Compounds and methods for use thereof in the treatment of cancer or viral infections | THE PROCTER & GAMBLE COMPANY | 2002-12-19 | — | — | US | disclosed |
| US-6462062-B1 | N-ESTER OR AMIDE SUBSTITUTED 2-AMINO-BENZIMIDAZOLES | THE PROCTER & GAMBLE COMPANY | 2002-10-08 | — | — | US | disclosed |
| US-6407105-B1 | 2-AMINO-1-CARBOXYBENZIMIDAZOLE DERIVATIVES; VIRICIDES, ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS | THE PROCTER & GAMBLE COMPANY | 2002-06-18 | — | — | US | disclosed |
| US-6380232-B1 | FOR THERAPY OF CANCER OR A VIRAL INFECTION IN WARM BLOODED ANIMALS, MAY BE USED IN COMBINATION WITH POTENTIATOR OR OTHER DRUG | THE PROCTER & GAMBLE COMPANY | 2002-04-30 | — | — | US | disclosed |
| WO-2002026716-A2 | BENZIMIDAZOLES AND METHODS FOR USE THEREOF IN THE TREATMENT OF CANCER OR VIRAL INFECTIONS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
| US-5326779-A | Method of inhibiting the advanced glycosylation of proteins using 1,2-disubstituted-benzimidazoles | THE ROCKEFELLER UNIVERSITY (US) | 1994-07-05 | — | — | US | disclosed |
| US-4065462-A | ORGANIC PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-4004016-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3981886-A | Amino-benzimidazole derivatives | E. R. SQUIBB & SONS, INC. (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | NUDT1 3082/4885PSMB8 2621/4885MASP2 1959/4885 |
| US-20170204098-A1 | NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | NUDT1 2826/4885PSMB8 4113/4885MASP2 589/4885 |
| US-20030100592-A1 | Compounds and methods for use thereof in the treatment of viral infections | PAICS, PIGO, BAD | NUDT1 26/4885PSMB8 3359/4885MASP2 895/4885 |
| US-20020193609-A1 | Compounds and methods for use thereof in the treatment of cancer or viral infections | PAICS, MCL1, BAD | NUDT1 18/4885PSMB8 3852/4885MASP2 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.